Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+
Article first published online: 30 JAN 2009
2003 British Pharmacological Society
British Journal of Pharmacology
Volume 139, Issue 5, pages 1014–1022, July 2003
How to Cite
Strokin, M., Sergeeva, M. and Reiser, G. (2003), Docosahexaenoic acid and arachidonic acid release in rat brain astrocytes is mediated by two separate isoforms of phospholipase A2 and is differently regulated by cyclic AMP and Ca2+. British Journal of Pharmacology, 139: 1014–1022. doi: 10.1038/sj.bjp.0705326
- Issue published online: 30 JAN 2009
- Article first published online: 30 JAN 2009
- (Received April 4, 2003, Accepted April 4, 2003)
- Protein kinase A;
- polyunsaturated fatty acids;
- lipid mediators;
- cyclic nucleotide;
- nucleotide receptor (P2Y receptor)
Docosahexaenoic acid (DHA) and arachidonic acid (AA), polyunsaturated fatty acids (PUFAs), are important for central nervous system function during development and in various pathological states. Astrocytes are involved in the biosynthesis of PUFAs in neuronal tissue. Here, we investigated the mechanism of DHA and AA release in cultured rat brain astrocytes.
Primary astrocytes were cultured under standard conditions and prelabeled with [14C]DHA or with [3H]AA. Adenosine 5′-triphosphate (ATP) (20 μM applied for 15 min), the P2Y receptor agonist, stimulates release of both DHA (289% of control) and AA (266% of control) from astrocytes. DHA release stimulated by ATP is mediated by Ca2+-independent phospholipase A2 (iPLA2), since it is blocked by the selective iPLA2 inhibitor 4-bromoenol lactone (BEL, 5 μM) and is not affected either by removal of Ca2+ from extracellular medium or by suppression of intracellular Ca2+ release through PLC inhibitor (U73122, 5 μM).
AA release, on the other hand, which is stimulated by ATP, is attributed to Ca2+-dependent cytosolic PLA2 (cPLA2). AA release is abolished by U73122 and, by removal of extracellular Ca2+, is insensitive to BEL and can be selectively suppressed by methyl arachidonyl fluorophosphonate (3 μM), a general inhibitor of intracellular PLA2 s.
Western blot analysis confirms the presence in rat brain astrocytes of 85 kDa cPLA2 and 40 kDa protein reactive to iPLA2 antibodies.
The influence of cAMP on regulation of PUFA release was investigated. Release of DHA is strongly amplified by the adenylyl cyclase activator forskolin (10 μM), and by the protein kinase A (PKA) activator dibutyryl-cAMP (1 mM). In contrast, release of AA is not affected by forskolin or dibutyryl-cAMP, but is almost completely blocked by 2,3-dideoxyadenosine (20 μM) and inhibited by 34% by H89 (10 μM), inhibitors of adenylyl cyclase and PKA, respectively.
Other neuromediators, such as bradykinin, glutamate and thrombin, stimulate release of DHA and AA, which is comparable to the release stimulated by ATP.
Different sensitivities of iPLA2 and cPLA2 to Ca2+ and cAMP reveal new pathways for the regulation of fatty acid release and reflect the significance of astrocytes in control of DHA and AA metabolism under normal and pathological conditions in brain.
British Journal of Pharmacology (2003) 139, 1014–1022. doi:10.1038/sj.bjp.0705326